vs

Side-by-side financial comparison of ICHOR HOLDINGS, LTD. (ICHR) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.

ICHOR HOLDINGS, LTD. is the larger business by last-quarter revenue ($223.6M vs $127.1M, roughly 1.8× Zai Lab Ltd). On growth, Zai Lab Ltd posted the faster year-over-year revenue change (17.1% vs -4.2%). ICHOR HOLDINGS, LTD. produced more free cash flow last quarter ($5.9M vs $-26.7M). Over the past eight quarters, Zai Lab Ltd's revenue compounded faster (20.8% CAGR vs 5.4%).

Ichor Holdings Ltd. designs, manufactures and supplies critical fluid delivery systems, subsystems and related components for the global semiconductor manufacturing sector. Its products are integrated into front-end wafer processing equipment, supporting production of advanced logic, memory and specialty chips for leading semiconductor device and equipment makers across North America, East Asia and Europe.

Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.

ICHR vs ZLAB — Head-to-Head

Bigger by revenue
ICHR
ICHR
1.8× larger
ICHR
$223.6M
$127.1M
ZLAB
Growing faster (revenue YoY)
ZLAB
ZLAB
+21.3% gap
ZLAB
17.1%
-4.2%
ICHR
More free cash flow
ICHR
ICHR
$32.6M more FCF
ICHR
$5.9M
$-26.7M
ZLAB
Faster 2-yr revenue CAGR
ZLAB
ZLAB
Annualised
ZLAB
20.8%
5.4%
ICHR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ICHR
ICHR
ZLAB
ZLAB
Revenue
$223.6M
$127.1M
Net Profit
$-16.0M
Gross Margin
9.4%
51.0%
Operating Margin
-6.2%
-54.6%
Net Margin
-7.1%
Revenue YoY
-4.2%
17.1%
Net Profit YoY
-304.8%
EPS (diluted)
$-0.46
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ICHR
ICHR
ZLAB
ZLAB
Q4 25
$223.6M
$127.1M
Q3 25
$239.3M
$115.4M
Q2 25
$240.3M
$109.1M
Q1 25
$244.5M
$105.7M
Q4 24
$233.3M
$108.5M
Q3 24
$211.1M
$101.8M
Q2 24
$203.2M
$100.1M
Q1 24
$201.4M
$87.1M
Net Profit
ICHR
ICHR
ZLAB
ZLAB
Q4 25
$-16.0M
Q3 25
$-22.9M
$-36.0M
Q2 25
$-9.4M
$-40.7M
Q1 25
$-4.6M
$-48.4M
Q4 24
$-3.9M
Q3 24
$-2.8M
$-41.7M
Q2 24
$-5.1M
$-80.3M
Q1 24
$-9.0M
$-53.5M
Gross Margin
ICHR
ICHR
ZLAB
ZLAB
Q4 25
9.4%
51.0%
Q3 25
4.6%
59.5%
Q2 25
11.3%
60.6%
Q1 25
11.7%
63.6%
Q4 24
11.6%
61.5%
Q3 24
13.2%
64.1%
Q2 24
12.6%
64.9%
Q1 24
11.4%
61.4%
Operating Margin
ICHR
ICHR
ZLAB
ZLAB
Q4 25
-6.2%
-54.6%
Q3 25
-8.1%
-42.3%
Q2 25
-2.0%
-50.3%
Q1 25
-0.5%
-53.3%
Q4 24
-0.5%
-62.6%
Q3 24
-0.2%
-66.6%
Q2 24
-1.1%
-76.0%
Q1 24
-1.9%
-80.7%
Net Margin
ICHR
ICHR
ZLAB
ZLAB
Q4 25
-7.1%
Q3 25
-9.6%
-31.2%
Q2 25
-3.9%
-37.3%
Q1 25
-1.9%
-45.8%
Q4 24
-1.7%
Q3 24
-1.3%
-40.9%
Q2 24
-2.5%
-80.2%
Q1 24
-4.5%
-61.4%
EPS (diluted)
ICHR
ICHR
ZLAB
ZLAB
Q4 25
$-0.46
$-0.05
Q3 25
$-0.67
$-0.03
Q2 25
$-0.28
$-0.04
Q1 25
$-0.13
$-0.04
Q4 24
$-0.11
$-0.09
Q3 24
$-0.08
$-0.04
Q2 24
$-0.15
$-0.08
Q1 24
$-0.30
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ICHR
ICHR
ZLAB
ZLAB
Cash + ST InvestmentsLiquidity on hand
$98.3M
$689.6M
Total DebtLower is stronger
$123.5M
Stockholders' EquityBook value
$663.9M
$715.5M
Total Assets
$942.9M
$1.2B
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ICHR
ICHR
ZLAB
ZLAB
Q4 25
$98.3M
$689.6M
Q3 25
$92.5M
$717.2M
Q2 25
$92.2M
$732.2M
Q1 25
$109.3M
$757.3M
Q4 24
$108.7M
$779.7M
Q3 24
$116.4M
$616.1M
Q2 24
$114.3M
$630.0M
Q1 24
$102.1M
$650.8M
Total Debt
ICHR
ICHR
ZLAB
ZLAB
Q4 25
$123.5M
Q3 25
$123.5M
Q2 25
$125.0M
Q1 25
$126.8M
Q4 24
$128.5M
Q3 24
$130.3M
Q2 24
$130.2M
Q1 24
$131.9M
Stockholders' Equity
ICHR
ICHR
ZLAB
ZLAB
Q4 25
$663.9M
$715.5M
Q3 25
$676.2M
$759.9M
Q2 25
$694.1M
$791.7M
Q1 25
$700.4M
$810.8M
Q4 24
$698.3M
$840.9M
Q3 24
$697.3M
$667.7M
Q2 24
$694.9M
$704.2M
Q1 24
$697.2M
$762.2M
Total Assets
ICHR
ICHR
ZLAB
ZLAB
Q4 25
$942.9M
$1.2B
Q3 25
$966.6M
$1.2B
Q2 25
$985.1M
$1.2B
Q1 25
$1.0B
$1.2B
Q4 24
$995.6M
$1.2B
Q3 24
$975.9M
$985.3M
Q2 24
$947.7M
$987.4M
Q1 24
$957.4M
$988.4M
Debt / Equity
ICHR
ICHR
ZLAB
ZLAB
Q4 25
0.19×
Q3 25
0.18×
Q2 25
0.18×
Q1 25
0.18×
Q4 24
0.18×
Q3 24
0.19×
Q2 24
0.19×
Q1 24
0.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ICHR
ICHR
ZLAB
ZLAB
Operating Cash FlowLast quarter
$9.2M
$-26.0M
Free Cash FlowOCF − Capex
$5.9M
$-26.7M
FCF MarginFCF / Revenue
2.6%
-21.0%
Capex IntensityCapex / Revenue
1.5%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-6.3M
$-158.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ICHR
ICHR
ZLAB
ZLAB
Q4 25
$9.2M
$-26.0M
Q3 25
$9.2M
$-32.0M
Q2 25
$-7.5M
$-31.0M
Q1 25
$19.0M
$-61.7M
Q4 24
$-2.5M
$-55.8M
Q3 24
$8.1M
$-26.8M
Q2 24
$17.5M
$-42.2M
Q1 24
$4.8M
$-90.1M
Free Cash Flow
ICHR
ICHR
ZLAB
ZLAB
Q4 25
$5.9M
$-26.7M
Q3 25
$2.1M
$-35.0M
Q2 25
$-14.8M
$-33.9M
Q1 25
$496.0K
$-63.2M
Q4 24
$-6.9M
$-58.4M
Q3 24
$2.2M
$-28.2M
Q2 24
$14.6M
$-42.9M
Q1 24
$314.0K
$-91.1M
FCF Margin
ICHR
ICHR
ZLAB
ZLAB
Q4 25
2.6%
-21.0%
Q3 25
0.9%
-30.4%
Q2 25
-6.2%
-31.1%
Q1 25
0.2%
-59.9%
Q4 24
-3.0%
-53.8%
Q3 24
1.0%
-27.7%
Q2 24
7.2%
-42.9%
Q1 24
0.2%
-104.5%
Capex Intensity
ICHR
ICHR
ZLAB
ZLAB
Q4 25
1.5%
0.5%
Q3 25
3.0%
2.6%
Q2 25
3.0%
2.6%
Q1 25
7.6%
1.5%
Q4 24
1.9%
2.4%
Q3 24
2.8%
1.3%
Q2 24
1.4%
0.7%
Q1 24
2.2%
1.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ICHR
ICHR

Other$101.6M45%
US$67.4M30%
Other Countries$29.7M13%
Europe$24.9M11%

ZLAB
ZLAB

Zejula$56.0M44%
Other$21.9M17%
Nuzyra$16.0M13%
Optune$11.9M9%
XACDURO$10.7M8%
Qinlock$9.7M8%
AUGTYRO$836.0K1%

Related Comparisons